Page 34 - 2021_07-Haematologica-web

N. Gagelmann and N. Kröger
Haploidentical transplant with posttrans- plant cyclophosphamide vs matched unre- lated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
84. Stern M, Wreede LC de, Brand R, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014;28(11):2235-2240.
85. Gökbuget N, Canaani J, Nagler A, Bishop M, Kröger N, Avigan D. Prevention and treat- ment of relapse after stem cell transplanta- tion with immunotherapy. Bone Marrow Transplant. 2018;53(6):664-672.
86. Falkenburg F, Ruggiero E, Bonini C, et al. Prevention and treatment of relapse after
stem cell transplantation by cellular thera- pies. Bone Marrow Transplant. 2019;54(1): 26-34.
87. Zeiser R, Beelen DW, Bethge W, et al. Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allo- geneic hematopoietic stem cell transplanta- tion. Biol Blood Marrow Transplant. 2019;25(4):e128-e140.
88. Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allo- geneic haematopoietic stem-cell transplanta- tion: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201-
1212.
89. Burchert A, Bug G, Fritz LV, et al. Sorafenib
maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem dupli- cation mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993-3002.
90. Ringdén O, Erkers T, Aschan J, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloab- lative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. 2013;274(2):153-162.
1804
haematologica | 2021; 106(7)